Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.

ABSTRACT:

Background

Over a dozen disease-modifying therapies (DMTs) have been approved for treatment of multiple sclerosis (MS). Treatment guidelines focus on when to initiate, change, and discontinue treatment but provide little guidance on how to select or sequence DMTs. This study assessed sequencing patterns of DMTs in patients with newly diagnosed MS.

Methods

Adults newly diagnosed with MS in the United States were identified from January 2007 to October 2017 using IBM MarketScan database. Patients had ≥12 months of continuous enrollment prior to diagnosis and ≥ 2 years of follow-up. Treatment pathways consisting of up to 3 DMT courses were reported, and each treatment course ended with discontinuation, switch, or end of follow-up.

Results

In total, 14,627 MS patients wer

SUBMITTER: Fox RJ 

PROVIDER: S-EPMC9172015 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature